Magrolimab Plus Rituximab/Chemo Delivers Responses in Relapsed/Refractory DLBCL
February 3rd 2023At 11.3 months of follow-up, magrolimab, rituximab, gemcitabine, and oxaliplatin yielded an overall response rate of 51.5%, including a complete response rate of 39.4%, among patients with relapsed or refractory diffuse large B-cell lymphoma.
Zanubrutinib Outperforms Ibrutinib in Head-to-Head Trial for Relapsed/Refractory CLL/SLL
January 11th 2023Zanubrutinib demonstrated a superior reduction in the risk of progression or death for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma compared with ibrutinib.
Second-Line Liso-Cel Continues to Improve Event-Free Survival in Large B-Cell Lymphoma
December 25th 2022In the second line setting, lisocabtagene maraleucel (liso-cel; Breyanzi) significantly reduced the risk of an event for patients with high-risk relapsed/refractory large B-cell lymphoma, compared with standard-of-care chemoimmunotherapy induction.
Real-World Patient-Reported Outcomes for Axi-Cel Align With Clinical Trial QOL, Symptomology Data
December 11th 2022Real-world data from patient-reported outcomes suggest that axicabtagene ciloleucel is associated with temporary worsening of quality of life with statistically and clinically significant improvements within 1-year postinfusion.
Liso-Cel Outperforms Standard Therapy in Improving QoL in Relapsed/Refractory LBCL
December 29th 2021A comparative analysis indicated that lisocabtagene maraleucel generated superior quality of life in patients with relapsed/refractory large B-cell lymphoma compared with the current standard of care.
Real-World Data Supports Clinical Benefit of Tisagenlecleucel in Relapsed/Refractory B-Cell ALL
December 14th 2021Tisagenlecleucel evoked similar efficacy and a preferrable safety profile in children and adults with B-ALL being treated in a real-world analysis, compared with the clinical trial ELIANA.